TEE
SLNO

Tibra Equities Europe’s Soleno Therapeutics SLNO Stock Holding History

Tibra Equities Europe’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,913
Closed -$341K – 174
2021
Q2 		$341K Buy
+19,913
New +$336K 0.11% 83

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tibra Equities Europe's SLNO Position: Q3 2021 in Review

Tibra Equities Europe sold out of Soleno Therapeutics (SLNO) in Q3 2021, closing a stake of 19,913 shares — an estimated $341K sold.

Tibra Equities Europe first reported a position in SLNO in Q2 2021 and held it in 1 quarter. The position peaked at $341K in Q2 2021. 39 funds tracked by Wall St. Rank hold SLNO as of Q3 2021.

  • Tibra Equities Europe reported no remaining Soleno Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 19,913 Soleno Therapeutics shares in Q3 2021, an estimated $341K.
  • Tibra Equities Europe first reported a position in Soleno Therapeutics in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Soleno Therapeutics position peaked at $341K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.